Tocilizumab

[kc_row use_container=”yes” force=”no” column_align=”middle” video_mute=”no” _id=”867898″][kc_column width=”12/12″ video_mute=”no” _id=”404355″][kc_column_text _id=”773739″]

An Insight of comparison between COVID-19 (2019-nCoV) and SARS-CoV in pathology and pathogenesis-10.31219/osf.io/hw34x.pdf

Clinical trial analysis of 2019-nCoV therapy registered in China-32108352.pdf

Development of therapeutic antibodies for the treatment of diseases-31894001.pdf

Efficacy and safety of chimeric antigen receptor-T-31923107.pdf

Insight into 2019 novel coronavirus — an updated intrim review andlessons from SARS-CoV and MERS-CoV-32247050.pdf

Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review-10.1101/2020.03.04.20031401

Protocolo de uso de Tocilizumab en el tratamiento de la neumonía intersticial por Covid-19 HUPH revisado 19032020.pdf

Reducing mortality from 2019-nCoV_ host-directed therapies should be an option-Correspondence-32035018.pdf

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)-10.1101/2020.02.18.20024364 .pdf

Response to Comments on Zhang et al_Clinical trial analysis of 2019‐nCoV therapy registered in China-32232977.pdf

The potential role of IL-6 in monitoring case of coronavirus disease 2019-10.2139/ssrn.3548761.pdf

Tocilizumab for the Treatment of Severe COVID-19-32369191.pdf

Tocilizumab treatment in COVID-19 a single center experience-32253759.pdf

[/kc_column_text][/kc_column][/kc_row]